Rhelion Life Sciences' subsidiary Filament Health has signed a supply and licensing agreement with the University of Southern California to provide PEX010, a patented botanical psilocybin drug candidate, for a clinical study on Psilocybin Assisted Mindfulness Therapy targeting depression. This deal highlights Filament's role as a leading supplier of pharmaceutical-grade natural psilocybin, supporting over 80 research studies globally. The study aims to explore whether mindfulness meditation can enhance psilocybin therapy's effectiveness. Rhelion acquired Filament Health earlier in 2026, gaining its patents and drug candidates, positioning the company strongly in the psychedelic drug development sector.
Rhelion Life Sciences' subsidiary Filament Health's recent agreement with the University of Southern California for a psilocybin drug study provides context for health sector trading. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 19:14 WIB: of 91 priced US health stocks, 28 rose and 59 fell. Notable prices include TWST at USD 133.00 with a 1-day change of -1.30%, FLNA at USD 0.73 up 1.28%, and ALC at USD 66.90 down 1.24%.
Mid-America Apartment Communities, Inc. (MAA), a major apartment REIT focused on the U.S. Sunbelt region, faces mixed analyst opinions as it prepares for the BofA Securities 2026 Global Real Estate Conference on September 16. Analysts have recently a...
UBS lowered its price target for Comcast from $32 to $27, citing expected higher broadband subscriber losses, weaker theme-park results, and lower revenue and EBITDA in the near term. Comcast is also undergoing a major restructuring to spin off NBCUn...
Hooker Furniture Corporation reported Q3 2026 revenue of $63.3 million and operating income of $1.3 million, beating consensus on profitability despite slightly missing revenue estimates. The company’s gross margin expanded significantly to 31.8%, la...
Backblaze received a Buy rating with a $16 price target due to strong growth in its B2 Cloud Storage segment, which saw 34% revenue growth in Q2. Core growth excluding price increases was about 26%, and new large AI contracts such as CoreWeave improv...
Robinhood and Webull shares fell about 4% as the U.S. Senate prepared to vote on the CLARITY Act, a bill aimed at establishing clearer regulations for cryptocurrency markets. The vote's outcome is uncertain, causing investor anxiety since both broker...
